Evaluation of Immunogenicity of Clostridium perfringens Type B Toxoid and Inactivated FMD (O) Virus with Adjuvant (ISA70-MF59)

Arch Razi Inst. 2023 Jun 30;78(3):907-913. doi: 10.22092/ARI.2022.360215.2565. eCollection 2023 Jun.

Abstract

Foot and mouth disease (FMD) and enterotoxemia are important diseases of hoofed animals. Vaccination against livestock pathogens, especially these two diseases, plays a key role in the prevention and control of these diseases. The use of combined vaccines with the aim of creating a better immune response and producing cheaper vaccines is a great contribution to Vaccine industry. This research aimed to compare the immunogenicity of FMD (O) and Clostridium perfringens type B toxoid along with adjuvant (MF59) and Montanide (ISA70) to create the best immunogenicity. To investigate the immune responses of vaccines, it was injected into an animal model, and the antibody titer was measured by enzyme-linked immunosorbent assay (ELISA) test and VN antibody titer. The results showed that the formulation with MF59 adjuvant brought more stable immunogenicity against FMD and Clostridium perfringens type B, and the length of the immunogenicity period also increased significantly. Therefore, the combined vaccine (Clostridium perfringens + FMD) could play a major role invaccine industry as an alternative vaccine against Clostridium perfringens and FMD in livestock.

Keywords: Combination vaccine; FMD; ISA70; MF59; Clostridium perfringens.

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Clostridium perfringens
  • Foot-and-Mouth Disease* / prevention & control
  • Toxoids
  • Viral Vaccines*

Substances

  • MF59 oil emulsion
  • Adjuvants, Immunologic
  • Viral Vaccines
  • Toxoids